Wednesday, October 27, 2021
HomeBusinessXORTX Announces Results of Mount Sinai COVID-19 Clinical Study

XORTX Announces Results of Mount Sinai COVID-19 Clinical Study

Early and high uric acid independently associated with acute kidney injury and mortality in COVID-19

Article content

CALGARY, Alberta, Oct. 14, 2021 (GLOBE NEWSWIRE) – XORTX Therapeutics Inc. (” XORTX “Wave” Company ”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapy company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce and share the results of a summary of the Society’s Kidney Week American Nephrology Program by Dr. Steven Coca and the Mount Sinai Hospital Network and Icahn School of Medicine team, to be published online Friday, October 15, 2021. This study was sponsored by XORTX Therapeutics Inc. and the reported findings support the provisional patent and XORTX filing applications announced. March 2020 and March 2021.

Commercial

Article content

This clinical study of patients hospitalized for COVID-19 between March 1, 2020 and December 31, 2020 characterized the association between high serum uric acid levels with major adverse kidney events (MAKE), as well as heart damage. Since its appearance, COVID-19 has been reported to be associated in some individuals with acute injury to the renal, cardiovascular, neurological, and other body systems. 1 The abstract presented online for the upcoming American Society of Nephrology presents data to support the conclusions that “In patients admitted to hospital for COVID-19, higher uric acid levels were independently associated with MAKE and mortality in a dose-dependent manner. Additionally, hyperuricemia was associated with higher levels of procalcitonin and troponin. “

Commercial

Article content

Procalcitonin concentrations and troponin concentrations are often used as markers for the interpretation of the severity of sepsis and cardiac injury, respectively. 2.3

Dr. Steven Coca commented: “Many factors are likely to play a role in contributing to acute kidney injury (AKI) in hospitalized COVID patients. The findings of our study highlight the importance of ordering a serum uric acid level in hospitalized patients upon admission or, at the latest, at the first appearance of clinical AKI, since hyperuricemia can be a modifiable risk factor (i.e. , treatable) of exacerbation of kidney injury. . “

Dr. Allen Davidoff stated, “XORTX is pleased to be able to draw attention to this important work and acceptance of this peer-reviewed abstract as well as its presentation at the Kidney Week meeting of the American Society of Nephrology. The data from this clinical study support our claim that hyperuricemia could be a key factor in acute kidney injury and now multi-organ injury in people hospitalized with COVID-19 infection. “

Commercial

Article content

Definition: MAKE Criteria is defined as: MAKE (Major Adverse Renal Events) is a composed of persistent impairment of kidney function (> 25% decrease in eGFR), new need for hemodialysis and death. MAKE was evaluated 30, 60, or 90 days after AKI diagnosis.

About COVID-19 and Acute Kidney Injury

Acute kidney injury (ARI) has been identified as an independent risk factor for hospital mortality in COVID-19 patients 5 . Recent data from the United States indicates that 25-35% of hospitalized COVID-19 patients develop AKI. 6-8 Up to 20% of them need renal replacement therapy (RRT), and the mortality rate in patients experiencing AKI in the context of COVID-19 is several times higher than in patients without AKI. Seventh Additionally, proteinuria (69-85%) and hematuria (50-65%) are common in COVID-19. 6-8 In previous peer-reviewed studies, viral infections such as influenza, when severe, can result in increased lung cell debris, endothelial cell debris, and serum uric acid (SUA) levels in the circulation, as well as an increased expression of cytokines. Coronavirus infection appears to follow this pattern.

Commercial

Article content

XORTX is developing XRx-101 a therapy designed to decrease elevated serum uric acid levels and inhibit purine metabolism by xanthine oxidase for the treatment and prevention of AKI in people with acute renal failure.

References:

  1. Gupta A_Extrapulmonary manifestations of COVID-19_Nature medicine_preprint_July10_2020s41591-020-0968-3
  2. Taylor R., Jones A., Kelly S., Simpson M., Mabey J., A Review of the Value of Procalcitonin as a Marker of Infection, Cureous 9 (4): e1148, 2017
  3. Babuin L., Jaffe AS, Troponin: the biomarker of choice for the detection of cardiac injury, CMAJ, 174 (3): 353, 2006
  4. Billings FT, Shaw AD, Clinical Trial Endpoints in Acute Kidney Injury, Nephron Clin Practice, 127
    (0): 89-93, 2014 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480222/#:~:text=MAKE%20(major%20adverse%20kidney%20events,90%20days%20following%20AKI%20diagnosis.
  5. Source: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
  6. Hirsch JS, Ng JH, Ross DW et al. Acute kidney injury in hospitalized patients with Covid-19. Kidney Int. 2020.
  7. Chan L, Chaudhary K, Saha A, et al. Acute kidney injury in hospitalized patients with COVID-19. medRxiv. 2020: 2020.2005.2004.20090944.
  8. Mohamed MM, Lukitsch I, Torres-Ortiz AE, et al. Acute kidney injury associated with coronavirus disease 2019 in urban New Orleans. Kidney 360. 2020: 10.34067 / KID.0002652020.

Commercial

Article content

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development: XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), XRx-101 for coronavirus / COVID-19 infection, and XRx-225 is a program of Preclinical stage for type 2 diabetic nephropathy (T2DN). XORTX is working to advance its products in clinical development that target aberrant metabolism of purines and xanthine oxidase to decrease or inhibit uric acid production. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com .

Commercial

Article content

For more information contact:
Allen Davidoff, CEO Nick Rigopulos, Director of Communications
[email protected] or +1 403 455 7727 [email protected] or +1 617 901 0785
Dr. David Sans, Director of Corporate Development in New York City
[email protected] or + 1347573 0541

The CSE and Nasdaq did not approve or disapprove the content of this press release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained.

This press release includes forward-looking statements that are subject to assumptions, risks, and uncertainties. Statements in this press release that are not purely historical are forward-looking statements, including but not limited to statements regarding the intentions, plans, estimates, beliefs or expectations of the Company. Although the Company believes that such intentions, plans, estimates, beliefs and expectations in this press release are reasonable, there can be no guarantee that such intentions, plans, beliefs and expectations will be accurate. The Company cautions readers that all forward-looking statements, including but not limited to those relating to the future operations and business prospects of the Company, are based on assumptions that cannot be guaranteed and are subject to certain risks and uncertainties that could cause actual events or results. differ materially from those indicated in the forward-looking statements. Readers are advised to rely on their own assessment of such risks and uncertainties and should not place undue reliance on forward-looking statements. Any forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements or update the reasons why actual events or results could or differ from those projected in the statements. prospective. . The Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Main logo

Commercial

Comments

Postmedia is committed to maintaining a lively but civilized discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to moderate before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications – you will now receive an email if you receive a response to your comment, there is an update from a comment thread you follow, or if a user you follow comments. Visit our Community Principles for more information and details on how to adjust your E-mail settings.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular